Hormonal treatment of unresectable pancreatic cancer with LHRH analogue (goserelin).
Recently non-controlled clinical trials reported encouraging results using a suppressive endocrine treatment in patients with unresectable pancreatic cancer. In this study 15 patients were given an LHRH analogue every 4 weeks (goserelin 3.6 mg), while 18 patients with advanced stage pancreatic carcinoma were given only symptomatic therapy. All patients treated with goserelin had sexual hormone suppression. Follow-up included abdominal ultrasound or computed tomography scan every 3 months; Ca 19-9 assay and routine laboratory blood tests were performed every month. No partial or complete response, no performance status or Ca 19-9 level changes were found. No significant difference in survival was seen in the two groups of patients. This study suggests that goserelin is unlikely to have a major influence on the survival of patients with advanced pancreatic carcinoma and casts further doubt upon the hormone-dependence of this neoplasm.
Sperti
C
C
Clinical Chirurgica I, Cattedra di Patologia Speciale Chirurgica, University of Padua, Italy.
Pasquali
C
C
Catalini
S
S
Cappellazzo
F
F
Bonadimani
B
B
Militello
C
C
Pedrazzoli
S
S
D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D006065:Gonadotropins, Pituitary / Q000097:blood; D017273:Goserelin; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D011446:Prospective Studies; D016019:Survival Analysis
D015295:Antigens, Tumor-Associated, Carbohydrate; D012739:Gonadal Steroid Hormones; D006065:Gonadotropins, Pituitary; D017273:Goserelin; D002064:Buserelin